#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Genetic Syndromes Predisposing to Tumors of Central Nervous System in Children


Authors: V. Krutílková
Authors‘ workplace: Gennet, Centrum lékařské genetiky a reprodukční medicíny, Praha
Published in: Klin Onkol 2016; 29(Supplementum 1): 71-77
Category: Review
doi: https://doi.org/10.14735/amko2016S71

Overview

Background:
The overall incidence of childhood malignancies is rather low. Central nervous system tumours constitute the largest group of solid tumours among children. In contrast to adult population, a genetic predisposition is frequently associated with these malignancies (it is assumed to occur in approximately 15–25% of all childhood tumours) and there is also a number of monogenic hereditary syndromes known to be associated with brain tumours.

Aim:
The purpose of this article is to present an overview of genetic syndromes reported to increase the risk of childhood central nervous system tumours. The outlined tumour predispositions are divided into two groups. Firstly, syndromes with multisystem manifestation, where neoplasia is one of the components, whereas the distinguishing symptom is usually non-oncological. Secondly, there are syndromes that are diagnosed by the associated neoplasm withou any other noticeable phenotypic manifestation. A brief description of particular diseases is provided with a focus on associated central nervous system tumours. Detection of a tumour predisposition in a child is important not only for the child itself, but also for its family relatives. Often, a modification of treatment is necessary in regards to a genetic diagnosis. With the evolution of personalised medicine the possibility of “tailored” therapy will probably be a demanded solution. Last but not least, it is crucial to provide the child with a specialised preventive care owing to the risk of another potential malignancy. The diagnosis of hereditary cancer predisposition has also a big impact on the relatives of the patient. It enables to specify their oncological risk and arrange a specialised preventive care program, if needed. For high-risk parents planning another pregnancy there is a possibility to prevent the transfer of a certain disposition with the aid of preimplantation and prenatal genetic testing.

Key words:
brain tumours –  child –  hereditary cancer syndromes

The authors declare she has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
15. 7. 2015

Accepted:
26. 8. 2015


Sources

1. Bleeker FE, Hopman SM, Merks JH et al. Brain tumors and syndromes in children. Neuropediatrics 2014; 45(3): 137– 161. doi: 10.1055/ s‑ 0034‑ 1368116.

2. Vil­lani A, Malkin D, Tabori U. Syndromes predispos­ing to pediatric central nervous system tumors: les­sons learned and new promises. Curr Neurol Neurosci Rep 2012; 12(2): 153– 164. doi: 10.1007/ s11910‑ 011‑ 0244‑ 5.

3. Vil­lavicencio EH, Walterhouse DO, Ian­naccone PM. The sonic hedgehog‑ patched‑ gli pathway in human development and disease. Am J Hum Genet 2000; 67(5): 1047– 1054.

4. Poduri A, Evrony GD, Cai X et al. Somatic mutation, genomic variation, and neurological disease. Science 2013; 341(6141): 1237758. doi: 10.1126/ science.1237758.

5. Petrák B, Plevová P, Novotný J et al. Neurfibromatosis von recklinghausen. Klin Onkol 2009; 22 (Suppl): S38– S44.

6. Plevová P, Krutílková V, Puchmajerová A, et al. Gorlinův syndrom. Klin Onkol 2009; 22 (Suppl): S34– S35.

7. Amlashi SF, Rif­faud L, Bras­sier G et al. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medul­loblastoma in infancy. A population‑based study and review of the literature. Cancer 2003; 98(3): 618– 624.

8. Choudry Q, Patel HC, Gurusinghe NT et al. Radiation‑induced brain tumors in nevoid basal cell carcinoma syndrome: implications for treatment and surveil­lance. Child Nerv Syst 2007; 23(1): 133– 136.

9. Foretová L, Macháčková E, Gail­lyová R et al. Hereditární nádorová onemocnění. In: Foretová L, Svoboda M, Slabý Oet al (eds). Molekulární genetika v onkologii. 1. vyd. Praha: Mladá fronta 2014.

10. Vrtěl R, Filipová H, Vodička R et al. Tuberózní skleróza. Klin Onkol 2009; 22 (Suppl): S50– S53.

11. Meyer S, Tischkowitz M, Chandler K et al. Fanconi anaemia, BRCA2 mutations and childhood cancer: a develop­mental perspective from clinical and epidemiological observations with implications for genetic counsel­ling. J Med Genet 2014; 51(2): 71– 75. doi: 10.1136/ jmedgenet‑ 2013‑ 101642.

12. Tischkowitz M, Xia B. PALB2/ FANCN –  recombin­ing cancer and Fanconi anemia. Cancer Res 2010; 70(19): 7353– 7359. doi: 10.1158/ 0008– 5472.CAN‑ 10- 1012.

13. Roelfsema JH, Peters DJ. Rubinstein‑Taybi syndrome: clinical and molecular overview. Expert Rev Mol Med 2007; 9(23): 1– 16.

14. Bourdeaut F, Miquel C, Richer W et al. Rubinstein‑Tay­bi syndrome predispos­ing to non‑WNT, non‑SHH, group 3medul­loblastoma. Pediatr Blood Cancer 2014; 61(2): 383– 386. doi: 10.1002/ pbc.24765.

15. Pol­lard JM, Gatti RA. Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol Biol Phys 2009; 74(5): 1323– 1331. doi: 10.1016/ j.ijrobp.2009.02.057.

16. Gonzales KD, Buzin CH, Noktner KA et al. High frequency of de novo mutations in Li‑ Fraumeni syndrome: impact on age at first dia­gnosis. J Med Genet 2009; 46(10): 686– 693. doi: 10.1136/ jmg.2008.058958.

17. Tinat J, Bougeard L, Ronsin M et al. 2009 version of the Chompret criteria for Li‑ Fraumeni syndrome. J Clin Oncol 2009; 27(26): e108– e109. doi: 10.1200/ JCO.2009.22.7967.

18. Gozali AE, Britt B, Shane L et al. Choroid plexus tumors; management, outcome, and as­sociation with the Li‑ Fraumeni syndrome: the Children’s Hospital Los Angeles (CHLA) experience, 1991– 2010. Pediatr Blood Cancer 2012; 58(6): 905– 909. doi: 10.1002/ pbc.23349.

19. Krutílková V, Trková M, Fleitz J et al. Identification of five families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer 2005; 41(11): 1597– 1603.

20. Vasen HF, Ghorbanoghli Z, Bourdeaut F et al. Guidelines for surveil­lance of individuals with constitutional mismatch repair‑ deficiency proposed by the European Consortium „Care for CM­mR‑ D“(C4CM­mR‑ D). J Med Genet 2014; 51(5): 283– 293. doi: 10.1136/ jmedgenet‑ 2013‑ 102238.

21. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009; 4: 22. doi: 10.1186- 1750- 1172- 4- 22.

22. Sun S, Liu AJ. Long/ term fol­low‑up studies of Gam­ma Knife surgery for patients with neurofibromatosis type 2. Neurosurg 2014; 121 (Suppl): 143– 149. doi: 10.3171/ 2014.8.GKS141503.

23. Bruggers CS, Bleyl SB, Pysher T et al. Clinicopathologic comparison of familial versus sporadic atypical teratoid/ rhabdoid tumors (AT/ RT) of the central nervous system. Pediatr Blood Cancer 2011; 56(7): 1026– 1031. doi:10.1002/ ppbc.22757.

24. Kan­no H, Kuratsu J, Nishikawa R et al. Clinical features of patients bear­ing central nervous system hemangioblastoma in von Hippel‑ Lindau disease. Acta Neurochir (Wien) 2013; 155(1): 1– 7. doi: 10.1007/ s00701‑ 012‑ 1514‑ y.

25. Scheinemann K, Bouf­fet E (eds). Pediatric neuro‑on-cology. New York: Springer‑ Verlag 2015.

26. Schif­fman JD, Gel­ler JI, Mundt E et al. Update on pediatric cancer predisposition syndromes. Pediatr Blood Cancer 2013; 60(8): 1247– 1252. doi: 10.1002/ pbc.24555.

Labels
Paediatric clinical oncology Surgery Clinical oncology

Article was published in

Clinical Oncology

Issue Supplementum 1

2016 Issue Supplementum 1

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#